Cantor Fitzgerald Has Negative View of FDMT FY2025 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings estimates for 4D Molecular Therapeutics in a note issued to investors on Monday, May 12th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of ($3.40) for the year, down from their prior estimate of ($3.22). The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02).

A number of other analysts have also recently commented on FDMT. Royal Bank of Canada cut their target price on 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Barclays reduced their price objective on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. The Goldman Sachs Group lowered their target price on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, Chardan Capital cut their target price on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating on the stock in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $29.56.

4D Molecular Therapeutics Price Performance

NASDAQ FDMT opened at $3.27 on Wednesday. The company has a fifty day moving average of $3.35 and a two-hundred day moving average of $5.20. The company has a market capitalization of $151.48 million, a PE ratio of -1.15 and a beta of 2.87. 4D Molecular Therapeutics has a 1 year low of $2.24 and a 1 year high of $28.93.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of FDMT. Y Intercept Hong Kong Ltd purchased a new position in 4D Molecular Therapeutics in the 1st quarter valued at $41,000. KLP Kapitalforvaltning AS acquired a new stake in shares of 4D Molecular Therapeutics in the 4th quarter worth $48,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of 4D Molecular Therapeutics in the 4th quarter worth $50,000. PNC Financial Services Group Inc. increased its stake in shares of 4D Molecular Therapeutics by 66.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock worth $51,000 after acquiring an additional 3,630 shares during the period. Finally, Daiwa Securities Group Inc. increased its stake in shares of 4D Molecular Therapeutics by 5,291.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock worth $55,000 after acquiring an additional 9,737 shares during the period. Institutional investors and hedge funds own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.